Denali Therapeutics Inc. Marketable Securities (Non-Current)
Denali Therapeutics Inc. (DNLI) had Marketable Securities (Non-Current) of $229.53 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:MarketableSecuritiesNoncurrent · last filed 2026-08-06
- 2026-06-30: Marketable Securities, Noncurrent $229.53M.
- 2026-03-31: Marketable Securities, Noncurrent $63.78M.
- 2025-12-31: Marketable Securities, Noncurrent $98.32M.
- 2025-09-30: Marketable Securities, Noncurrent $24.70M.
| Period end | Marketable Securities, Noncurrent |
|---|---|
| 2026-06-30 | $229.53M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $63.78M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $98.32M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $24.70M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $78.46M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $235.84M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $359.37M 10-K · filed 2026-02-26 |
| 2024-09-30 | $445.46M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $450.99M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $490.72M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2023-09-30 | $7.91M 10-Q · filed 2023-11-07 |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-07 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 |
| 2022-06-30 | $94.22M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $250.27M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $425.45M 10-K · filed 2023-02-27 |
| 2021-09-30 | $319.47M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $92.52M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $38.88M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $32.70M 10-K · filed 2022-02-28 |
| 2020-09-30 | $20.34M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $7.23M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $9.68M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $39.89M 10-K · filed 2021-02-26 |
| 2019-09-30 | $23.53M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $55.83M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $97.55M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $147.88M 10-K · filed 2020-02-27 |
| 2018-09-30 | $142.17M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $178.70M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $219.41M 10-Q · filed 2018-05-11 |
| 2017-12-31 | $60.75M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |